COMPANY PROFILE

Neuraly

Explore full profile

Discovering and developing treatments for neurodegenerative diseases

Gaithersburg, United StatesFounded 2016Biotech & Life Sciences

Valuation $100–250M Last recorded · 2018

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Neuraly

Neuraly, Inc. is a clinical-stage biopharmaceutical company dedicated to developing groundbreaking treatments for neurodegenerative diseases. Founded by renowned scientists and physicians, Neuraly focuses on translating scientific discoveries in neurology into innovative drugs that can significantly improve and extend the lives of patients suffering from conditions such as Alzheimer's, Parkinson's, and other neurodegenerative disorders. The company operates in the biopharmaceutical market, targeting a niche segment with high unmet medical needs. Neuraly's business model involves extensive research and development (R&D) to identify novel drug targets, followed by clinical trials to validate the efficacy and safety of these treatments. Revenue is primarily generated through partnerships, grants, and potential future sales of approved drugs. The company serves patients, healthcare providers, and the broader medical community by offering advanced therapeutic options that address chronic, progressive, and often fatal diseases.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Gaithersburg, United States
Employees: 17
Open positions: None listed
Dealroom signal: 73.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Jul 2018	$36M	$144M	Geon Investment · LB Investment · Magna Investment · D&D Pharmatech	—
ANGELEquity / VC	Sep 2016	$0	—	Boston Harbor Angels	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Neuraly website traffic

Latest recorded traffic for Neuraly is 340 monthly website visits, down 27.7% over the last three months. Neuraly's team declined 5.6% over the past year.

Latest monthly visits340 3-month web change-27.7% 1-year team growth-5.6%

Monthly website visitsJun 2018–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
XBxCystence BioTherapeutics for Polycystic Kidney Disease treatment	District of Tuggeranong, Australia	Operational	3	$485K	—
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
AIAiberRemote medical support technology for aviation and maritime	Winshill, United Kingdom	Operational
EHEdifice HealthOffers inflammatory health monitoring tests to help manage chronic inflammation and improve overall health and longevity	San Mateo, United States	Operational
NENeomorphDeveloping novel drugs targeting previously untreatable disease-causing proteins using molecular degradation technology	San Diego, United States	Operational
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational
GEGelmetixInjectable polymer gel for non-surgical chronic pain treatment	London, United Kingdom	Operational